Cover
Cover | 12 Months Ended |
Dec. 31, 2022 | |
Document Information [Line Items] | |
Document Type | DEF 14A |
Amendment Flag | false |
Entity Information [Line Items] | |
Entity Registrant Name | GE HealthCare Technologies Inc. |
Entity Central Index Key | 0001932393 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure | 12 Months Ended | |
Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Pay vs Performance Disclosure [Table] | ||
Pay vs Performance [Table Text Block] | Year Summary Compensation ($) Compensation 1 ($) Average Average 1 ($) Value of Initial Fixed $100 2 : Net Income 3 ($) Company Selected Performance Measure - Organic Revenue Growth 4 Company Total Shareholder Return Peer Group Total Shareholder Return 2022 10,497,102 7,343,420 4,663,530 2,921,756 N/A N/A 1,916,000,000 7.3 % | |
Company Selected Measure Name | Organic revenue growth | |
PEO Total Compensation Amount | $ 10,497,102 | |
PEO Actually Paid Compensation Amount | 7,343,420 | |
Non-PEO NEO Average Total Compensation Amount | 4,663,530 | |
Non-PEO NEO Average Compensation Actually Paid Amount | $ 2,921,756 | |
Equity Valuation Assumption Difference, Footnote [Text Block] | Compensation actually paid to our PEO and the average compensation actually paid to our non-PEO NEOs reflects adjustments from total compensation reported in the Summary Compensation Table. The assumptions used to calculate the values for RSUs and PSUs included in the calculation of compensation actually paid did not differ materially from those used to calculate grant date fair value for such awards. The assumptions used to calculate the value for stock options did not differ materially from those used to calculate grant date fair value for such awards. A Monte Carlo simulation model was used to calculate the fair value for PSUs. A Black-Scholes value was used for Options as of the applicable year-end or vesting date(s), determined using the same methodology used to determine grant date fair value, except that (a) the closing stock price on the applicable revaluation date was used as the current market price and (b) a reduced expected life was used, given applicable time lapse since grant date. | |
Tabular List [Table Text Block] | Three Most Important Measures for Linking NEO Pay to Company Performance • Organic revenue growth • Operating profit • Free cash flow | |
Net Income (Loss) | $ 1,916,000,000 | |
Company Selected Measure Amount | 0.073 | |
Additional 402(v) Disclosure [Text Block] | GE HealthCare became an independent, public company effective January 3, 2023, but was required to report pursuant to Section 13(a) or 15(d) of the Exchange Act effective as of December 8, 2022.As reported in the 2022 Form 10-K. | |
Measure [Axis]: 1 | ||
Pay vs Performance Disclosure [Table] | ||
Measure Name | Organic revenue growth | |
Non-GAAP Measure Description [Text Block] | Organic revenue for 2022 and 2021 was $18,873 million and $17,585 million, respectively, as reported in the 2022 Form 10-K. | |
Measure [Axis]: 2 | ||
Pay vs Performance Disclosure [Table] | ||
Other Performance Measure Amount | 18,873,000,000 | 17,585,000,000 |
Measure Name | Operating profit | |
Measure [Axis]: 3 | ||
Pay vs Performance Disclosure [Table] | ||
Measure Name | Free cash flow |